PMID- 22226572
OWN - NLM
STAT- MEDLINE
DCOM- 20120723
LR  - 20181201
IS  - 1532-2688 (Electronic)
IS  - 1059-1311 (Linking)
VI  - 21
IP  - 3
DP  - 2012 Apr
TI  - Short-term efficacy and safety of zonisamide as adjunctive treatment for 
      refractory partial seizures: a multicenter open-label single-arm trial in Korean 
      patients.
PG  - 188-93
LID - 10.1016/j.seizure.2011.12.005 [doi]
AB  - OBJECTIVE: To evaluate the efficacy and safety of adjunctive zonisamide (ZNS) 
      therapy in Korean adults with uncontrolled partial epilepsy. METHODS: Study 
      patients had an average of at least one seizure per 4-week (averaged over a 
      12-week historical baseline) despite the use of one to three antiepileptic drugs. 
      The starting dose of ZNS was 100mg/day, and was increased to 200mg/day after 
      2weeks. During the 12-week maintenance period, the dose of ZNS was adjusted to 
      200-400mg/day based on the physicians' discretion. The global evaluation scale 
      (GES) and quality of life (QOLIE-31) were also evaluated. RESULTS: A total of 121 
      patients were enrolled, of which 88 patients completed the study. The median 
      percent reduction in weekly seizure frequency over the treatment period was 
      59.0%. The >/=50% and >/=75% responder rates were 57.3% and 38.5%, respectively. 
      Seizure freedom over the treatment period was observed in 25 patients, but 
      seizure freedom throughout the 16-week treatment period was attained in only 16 
      patients. On investigator's GES, 84 patients were considered improved, with 33 
      patients showing marked improvement. In QOLIE-31 scale, seizure worry improved 
      significantly but emotional well-being deteriorated. Treatment-emergent adverse 
      events (AEs) were reported in 80 patients. The most common AEs were dizziness 
      (28.1%), somnolence (24.0%), anorexia (18.2%), headache (14.0%), nausea (13.2%), 
      and weight loss (10.7%). Twenty-two patients discontinued the trial due to 
      drug-related AEs. CONCLUSIONS: Our results suggest that adjunctive ZNS therapy 
      for the treatment of refractory partial epilepsy, though efficacious, is 
      associated with significant tolerability problems.
CI  - Copyright A(c) 2011 British Epilepsy Association. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Heo, Kyoung
AU  - Heo K
AD  - Department of Neurology, Severance Hospital, Seoul, Republic of Korea.
FAU - Lee, Byung In
AU  - Lee BI
FAU - Yi, Sang Do
AU  - Yi SD
FAU - Cho, Yong Won
AU  - Cho YW
FAU - Shin, Dong Jin
AU  - Shin DJ
FAU - Song, Hong Ki
AU  - Song HK
FAU - Kim, Ok Joon
AU  - Kim OJ
FAU - Park, Sung-Pa
AU  - Park SP
FAU - Kim, Sung Eun
AU  - Kim SE
FAU - Kim, Sang Ho
AU  - Kim SH
FAU - Lee, Jun Hong
AU  - Lee JH
FAU - Kim, Kyu-Sik
AU  - Kim KS
FAU - Lee, Se-Jin
AU  - Lee SJ
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20120104
PL  - England
TA  - Seizure
JT  - Seizure
JID - 9306979
RN  - 0 (Anticonvulsants)
RN  - 0 (Isoxazoles)
RN  - 459384H98V (Zonisamide)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anticonvulsants/*administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Epilepsies, Partial/*drug therapy
MH  - Female
MH  - Humans
MH  - Isoxazoles/*administration & dosage/adverse effects
MH  - Korea
MH  - Male
MH  - Middle Aged
MH  - Seizures/*drug therapy
MH  - Young Adult
MH  - Zonisamide
EDAT- 2012/01/10 06:00
MHDA- 2012/07/24 06:00
CRDT- 2012/01/10 06:00
PHST- 2011/09/27 00:00 [received]
PHST- 2011/12/06 00:00 [revised]
PHST- 2011/12/08 00:00 [accepted]
PHST- 2012/01/10 06:00 [entrez]
PHST- 2012/01/10 06:00 [pubmed]
PHST- 2012/07/24 06:00 [medline]
AID - S1059-1311(11)00317-7 [pii]
AID - 10.1016/j.seizure.2011.12.005 [doi]
PST - ppublish
SO  - Seizure. 2012 Apr;21(3):188-93. doi: 10.1016/j.seizure.2011.12.005. Epub 2012 Jan 
      4.